Drägerwerk confirms 2026 outlook. Drägerwerk stock sits 18.98 percent below its high

Published on 10/27/2026 at 15:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 EBIT fell to EUR 48.00 million as order intake rose 7.00 percent. Drägerwerk stock costs EUR 101.60 on October 27, 2026 versus EUR 102.40 Xetra close.

Drägerwerk's margin test

Third-quarter EBIT fell to EUR 48.00 million while order intake rose 7.00 percent.
The 5.60 percent EBIT margin was below the 6.00 to 8.00 percent fiscal-year 2026 target range.
The stock was at EUR 101.60 at Lang & Schwarz on October 27, 2026, down 0.78 percent versus the EUR 102.40 Xetra close of October 26, 2026.

Drägerwerk, DE0005550636, Illustration mit AI erstellt.

Drägerwerk (ISIN DE0005550636) reported third-quarter EBIT of EUR 48.00 million on October 14, 2026, while order intake rose 7.00 percent to EUR 926.00 million, according to the EQS News release. The new conclusion is clear: demand is improving faster than operating earnings, making margin conversion the key test before the full quarterly report.

Orders outpace quarterly revenue

Revenue increased 2.10 percent to EUR 851.00 million in the third quarter of 2026, compared with EUR 833.30 million a year earlier. Order intake reached EUR 926.00 million, up from EUR 856.10 million, creating a wider gap between incoming business and recognized sales.

Safety Technology supplied the strongest operating signal. Its order intake rose 20.20 percent to EUR 452.00 million, while Medical Technology order intake fell 3.00 percent to EUR 474.00 million. The split makes the group result more dependent on the conversion of safety-related demand into revenue and profit.

What does the margin gap mean?

The third-quarter EBIT margin was 5.60 percent, below the company's fiscal-year 2026 target range of 6.00 to 8.00 percent. The result included EUR 20.10 million in customs-duty refunds, while higher functional expenses weighed on earnings.

Drägerwerk kept its fiscal-year 2026 outlook for currency-adjusted revenue growth of 2.00 to 6.00 percent and an EBIT margin of 6.00 to 8.00 percent. The official Dräger investor-relations calendar schedules the detailed third-quarter report for October 29, 2026.

Stock stays below EUR 102.40

For investors, the upcoming report must show whether the stronger order book can lift profitability without another one-off contribution. At Lang & Schwarz, Drägerwerk stock was trading at EUR 101.60 on October 27, 2026, at 3:39 p.m. CET, down 0.78 percent versus the Xetra close of October 26, 2026 at EUR 102.40.

The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.